Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 16;60(11):e0057522.
doi: 10.1128/jcm.00575-22. Epub 2022 Aug 15.

Meningococcal Urethritis: Old and New

Bethany L Burns  1 , Daniel D Rhoads  1   2   3
Affiliations
Review

Meningococcal Urethritis: Old and New

Bethany L Burns et al. J Clin Microbiol. .

Abstract

Neisseria meningitidis is a common commensal bacterium found in the respiratory tract, but it can also cause severe, invasive disease. Vaccines have been employed which have been successful in helping to prevent invasive disease caused by encapsulated N. meningitidis from the A, C, W, Y, and B serogroups. Currently, nonencapsulated N. meningitidis groups are more common commensals in the population than in the prevaccine era. One emerging nonencapsulated group of bacteria is the U.S. N. meningitidis urethritis clade (US_NmUC), which can cause meningococcal urethritis in men. US_NmUC has unique genotypic and phenotypic features that may increase its fitness in the male urethra. It is diagnostically challenging to identify and distinguish meningococcal urethritis from Neisseria gonorrhoeae, as the clinical presentation and microbiological findings are overlapping. In this review, the history of meningococcal urethritis, emergence of US_NmUC, laboratory diagnosis, and clinical treatment are all explored.

Keywords: Neisseria meningitidis; US_NmUC; meningococcal urethritis; urethritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. D.D.R. has received compensation from Luminex, Talis Biomedical, and Roche for scientific advisory. D.D.R. has sponsored agreements through his employer with the following groups: Abbott, Accelerate Diagnostics, Altona, BD, BioFire, bioMerieux, Bio-Rad, Cepheid, Cleveland Diagnostics, HelixBind, Hologic, Luminex, Qiagen, Q-Linea, Roche, Specific Diagnostics, Thermo Fisher, and Vela Diagnostics. D.D.R. is a co-investigator with NIH/NIAID R01 HS028633-01.

References

    1. Seifert HS. 2019. Location, location, location—commensalism, damage and evolution of the pathogenic Neisseria. J Mol Biol 431:3010–3014. doi:10.1016/j.jmb.2019.04.007. - DOI - PubMed
    1. Weyand NJ. 2017. Neisseria models of infection and persistence in the upper respiratory tract. Pathog Dis 75:ftx031. doi:10.1093/femspd/ftx031. - DOI - PubMed
    1. Liu G, Tang CM, Exley RMY. 2015. Non-pathogenic Neisseria: members of an abundant, multi-habitat, diverse genus. Microbiology (Reading) 161:1297–1312. doi:10.1099/mic.0.000086. - DOI - PubMed
    1. Castelblanco RL, Lee M, Hasbun R. 2014. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 14:813–819. doi:10.1016/S1473-3099(14)70805-9. - DOI - PubMed
    1. Brooks R, Woods CW, Benjamin DK, Jr., Rosenstein NE. 2006. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. Clin Infect Dis 43:49–54. doi:10.1086/504804. - DOI - PubMed